A detailed review of Moderna’s business shows the company grappling with slumping Covid vaccine sales, canceled government contracts and major cuts to workforce and spending plans. Washington cancelled a $766 million preparedness contract and Moderna’s market capitalization has contracted sharply from its 2021 peak. The company retains cash reserves and pipeline programs, including a cancer vaccine, but faces investor and government pressure to show near‑term returns.